Dr. Albert Metz has been appointed as a managing director in BRG’s New York office, specifically for the Antitrust & Competition Policy and Financial Services Litigation & Investigations groups, as announced by the firm.
Metz possesses extensive knowledge and experience in economic and litigation consulting, specifically in areas such as credit markets, bankruptcies, asset pricing, monopolization, market manipulation, fixed-income securities, and debt derivatives.
Metz has extensive experience in various industries, including cryptocurrencies, multisided transaction platforms, insurance, healthcare, telecommunications, real estate, and financial institutions. He has previously worked with the US Department of Justice and Federal Trade Commission. Additionally, he has provided testimony on event study methodologies and market efficiency for both the US Securities and Exchange Commission and defendants in bankruptcy proceedings.
Read more: BRG Nabs Dr. Rosa Abrantes-Metz For Their Competition Policy Group
Metz is the latest addition to BRG’s world-leading antitrust and competition practice, following the recent appointments of renowned experts Dr. David S. Evans and Dr. Rosa M. Abrantes-Metz and the September appointment of distinguished antitrust economist Dr. David Sunding.
“Albert is an important addition to our fast-growing antitrust and competition practice, given his modeling work in fixed-income securities and complex debt and equity derivatives,” Sunding said. “His expertise will be incredibly valuable to BRG clients. I look forward to working with him as we continue to grow our antitrust and securities litigation capabilities.”
Commenting on his appointment, Metz said, “It’s an exciting time to join BRG as the firm expands its antitrust and competition practice and securities litigation capabilities. I look forward to contributing to the group’s continued expansion.”
Featured News
Judge Appoints Law Firms to Lead Consumer Antitrust Litigation Against Apple
Dec 22, 2024 by
CPI
Epic Health Systems Seeks Dismissal of Antitrust Suit Filed by Particle Health
Dec 22, 2024 by
CPI
Qualcomm Secures Partial Victory in Licensing Dispute with Arm, Jury Splits on Key Issues
Dec 22, 2024 by
CPI
Google Proposes Revised Revenue-Sharing Limits Amid Antitrust Battle
Dec 22, 2024 by
CPI
Japan’s Antitrust Authority Expected to Sanction Google Over Monopoly Practices
Dec 22, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – CRESSE Insights
Dec 19, 2024 by
CPI
Effective Interoperability in Mobile Ecosystems: EU Competition Law Versus Regulation
Dec 19, 2024 by
Giuseppe Colangelo
The Use of Empirical Evidence in Antitrust: Trends, Challenges, and a Path Forward
Dec 19, 2024 by
Eliana Garces
Some Empirical Evidence on the Role of Presumptions and Evidentiary Standards on Antitrust (Under)Enforcement: Is the EC’s New Communication on Art.102 in the Right Direction?
Dec 19, 2024 by
Yannis Katsoulacos
The EC’s Draft Guidelines on the Application of Article 102 TFEU: An Economic Perspective
Dec 19, 2024 by
Benoit Durand